9.9.2019
EN
Official Journal of the European Union
C 305/8
Judgment of the Court (Fourth Chamber) of 3 July 2019 — Viridis Pharmaceutical Ltd. v European Union Intellectual Property Office (EUIPO), Hecht-Pharma GmbH
(Case C-668/17 P) (1)
(Appeal - European Union trade mark - Revocation proceedings - Word mark Boswelan - No genuine use - Use of the mark in a clinical trial prior to filing an application for authorisation to place a medicinal product on the market - Proper reason for non-use - Concept)
(2019/C 305/09)
Language of the case: German
Parties
Appellant: Viridis Pharmaceutical Ltd. (represented by C. Spintig, S. Pietzcker and M. Prasse, Rechtsanwälte)
Other parties to the proceedings: European Union Intellectual Property Office (EUIPO) (represented by S. Hanne, acting as Agent), Hecht-Pharma GmbH (represented by J. Sachs and C. Sachs, Rechtsanwälte)
Operative part of the judgment
The Court:
1.
Dismisses the action;
2.
Orders Viridis Pharmaceutical Ltd to pay, in addition to its own costs, those incurred by the European Union Intellectual Property Office (EUIPO) and Hecht-Pharma GmbH.
(1) OJ C 83, 5.3.2018.